2-{4-[(8-chloroquinolin-2-yl)amino]phenoxy}ethan-1-ol | 1050479-34-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-{4-[(8-chloroquinolin-2-yl)amino]phenoxy}ethan-1-ol
• 英文别名: 5,8-dimethyl-6(5-methyl-pyridin-2-ylamine)-isoquinoline；5,8-dimethyl-N-(5-methylpyridin-2-yl)isoquinolin-6-amine
• CAS: 1050479-34-9
• 化学式: C₁₇H₁₇N₃
• 分子量: 263.342
• InChiKey: PRWOBUDMRAPIGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-溴-5-甲基吡啶 、 amino-6 dimethyl-5,8 isoquinoleine 在 palladium diacetate caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 叔丁醇 为溶剂， 生成 2-{4-[(8-chloroquinolin-2-yl)amino]phenoxy}ethan-1-ol
  参考文献：
  名称：

  [EN] COMPOUNDS USEFUL FOR TREATING CANCER
  [FR] COMPOSÉS UTILES POUR LE TRAITEMENT DU CANCER

  摘要：

  公开号：

  WO2010143168A3

文献信息

• [EN] BICYCLIC COMPOUNDS USEFUL FOR TREATING DISEASES CAUSED BY RETROVIRUSES<br/>[FR] COMPOSÉS BICYCLIQUES UTILES POUR LE TRAITEMENT DE MALADIES CAUSÉES PAR DES RÉTROVIRUS
  申请人：SPLICOS

  公开号：WO2015001518A1

  公开（公告）日：2015-01-08

  Described herein are methods for preventing or treating a retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection. In certain aspects, the methods described herein include contacting a cell in need thereof with compound (I), wherein (II) means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a –CN group, a hydroxyl group, a –COOR1 group, a (C1 -C3)fluoroalkyl group, a (C1 -C3)fluoroalkoxy group, a –NO2 group, a –NR1R2 group, a (C1-C4)alkoxy group, a phenoxy group and a (C1-C3)alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n' is 1 or 2, R' is a hydrogen atom, a halogen atom or a group chosen among a (C1-C3)alkyl group,, a hydroxyl group, a –COOR1 group, a –NO2 group, a –NR1R2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (C1-C3)fluoroalkyl group, a (C1-C4)alkoxy group and a –CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, to prevent or treat the retroviral infection and/or for preventing, inhibiting or treating a disease caused by the retroviral infection, wherein the retroviral infection is not HIV and the disease caused by the retroviral infection is not AIDS.

  本文描述了一种预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病的方法。在某些方面，所述方法包括将化合物(I)与需要其治疗的细胞接触，其中(II)表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟代烷基团、(C1-C3)氟代烷氧基团、-NO2基团、-NR1R2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(C1-C3)烷基团、羟基基团、-COOR1基团、-NO2基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(C1-C3)氟代烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，以预防或治疗逆转录病毒感染和/或预防、抑制或治疗由逆转录病毒感染引起的疾病，其中逆转录病毒感染不是HIV，由逆转录病毒感染引起的疾病不是艾滋病。
• COMPOUNDS USEFUL FOR TREATING PREMATURE AGING AND IN PARTICULAR PROGERIA
  申请人：Tazi Jamal

  公开号：US20120329796A1

  公开（公告）日：2012-12-27

  The present invention relates to compound (I) wherein: means a pyridazine, a pyrimidine or a pyrazine group, R independently represent a hydrogen atom, a halogen atom or a group chosen among a —CN group, a hydroxyl group, a —COOR 1 group, a (C 1 -C 3 )fluoroalkyl group, a (C 1 -C 3 )fluoroalkoxy group, a —NO2 group, a —NRiR2 group, a (C 1 -C 4 )alkoxy group, a phenoxy group and a (C 1 -C 3 )alkyl group, said alkyl being optionally mono-substituted by a hydroxyl group, n is 1, 2 or 3, n′ is 1 or 2, R′ is a hydrogen atom, a halogen atom or a group chosen among a (Ci-C3)alkyl group, a hydroxyl group, a —COOR 1 group, a —NO2 group, a —NR 1 R 2 group, a morpholinyl or a morpholino group, a N-methylpiperazinyl group, a (Ci-C3)fluoroalkyl group, a (C 1 -C 4 )alkoxy group and a —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C, for use as an agent for preventing, inhibiting or treating pathological or nonpathological conditions linked with premature aging. Some of said compounds are new and also form part of the invention.

  本发明涉及化合物(I)，其中：表示吡啶嗪、嘧啶或吡嗪基团，R独立地表示氢原子、卤素原子或在-CN基团、羟基基团、-COOR1基团、(C1-C3)氟烷基团、(C1-C3)氟烷氧基团、-NO2基团、-NRiR2基团、(C1-C4)烷氧基团、苯氧基团和(C1-C3)烷基团中选择的一种基团，所述烷基可以选择性地被一个羟基基团单取代，n为1、2或3，n'为1或2，R'为氢原子、卤素原子或在(Ci-C3)烷基团、羟基基团、-COOR1基团、-NO2基团、-NR1R2基团、吗啉基或吗啉基团、N-甲基哌嗪基团、(Ci-C3)氟烷基团、(C1-C4)烷氧基团和-CN基团中选择的一种基团，Z为N或C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C，用作预防、抑制或治疗与早衰有关的病理或非病理状态的药剂。其中一些化合物是新的，也是本发明的一部分。
• NOVEL COMPOUNDS DERIVED FROM INDOLE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Lejeune Fabrice

  公开号：US20110003843A1

  公开（公告）日：2011-01-06

  The present invention relates to a compound derived from indole corresponding to the following formula II: wherein X represents N, CR8 or N + R8, wherein R8 represents a hydrogen atom, a hydroxyl or alkyl or methoxy group optionally substituted with a phenyl group; R2, R3 and R4 independently represent a hydrogen atom or a halogen atom or an optionally substituted alkyl, amine, alkene, ester, sulfonamide, ether or benzyl group; R5 represents a hydrogen atom or an optionally substituted, saturated or unsaturated alkyl group, amine, benzyl group; R6 represents an optionally substituted C1-C3 alkyl group; R7 represents a hydrogen atom or an optionally substituted C1-C3 alkyl group and R7 is absent when the ring A is in the b position, and A represents a ring; R9 and R10 represent together a carbon bond or independently represent an R11 OR11, SR11 group; wherein R11 represents a hydrogen atom, an optionally substituted, saturated or unsaturated, C1-C3 alkyl group, which may contain one or more sulfur, oxygen or nitrogen atoms; pharmaceutically acceptable salts of said compounds, their isomers and/or a mixture thereof; pharmaceutical composition comprising such a compound; the use of such a compound for preparing a drug intended to treat a genetic disease resulting from at least one mutation causing the occurrence of an early termination codon.

  本发明涉及一种从吲哚衍生的化合物，对应于以下公式II： 其中，X表示N，CR8或N+R8，其中R8表示氢原子，羟基或烷基或甲氧基，可选地取代为苯基；R2、R3和R4分别表示氢原子或卤素原子或可选地取代的烷基、胺基、烯烃、酯、磺酰胺、醚或苄基；R5表示氢原子或可选地取代的饱和或不饱和烷基、胺基、苄基；R6表示可选地取代的C1-C3烷基；R7表示氢原子或可选地取代的C1-C3烷基，当环A在b位置时，R7不存在；A表示一个环；R9和R10共同表示碳键，或分别表示R11 OR11、SR11基团；其中，R11表示氢原子、可选地取代的饱和或不饱和的C1-C3烷基，可以含有一个或多个硫、氧或氮原子；该化合物的药学可接受盐、其异构体和/或混合物；包括这种化合物的药物组合物；使用这种化合物制备用于治疗由至少一个突变引起的早期终止密码子出现的遗传疾病的药物。
• New chemical molecules that inhibit the splicing mechanism for treating diseases resulting from splicing anomalies
  申请人：Splicos

  公开号：EP2266972A1

  公开（公告）日：2010-12-29

  The present invention relates to a compound of the formula I; a pharmaceutical composition comprising at least one such compound; and the use of such compound in preparing a drug to treat, in a subject, a genetic disease resulting from at least one splicing anomaly.

  本发明涉及一种式 I 的化合物；一种包含至少一种此类化合物的药物组合物；以及使用此类化合物制备药物，以治疗受试者因至少一种剪接异常而导致的遗传疾病。
• Compounds useful for treating AIDS
  申请人：ABIVAX

  公开号：US10017498B2

  公开（公告）日：2018-07-10

  A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R′ is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R″ is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n′ is 1 or 2.

  具有下式的化合物或其药学上可接受的盐： 其中 R 独立地代表氢原子、卤素原子、(C1-C3)烷基、-NR1R2 基团、(C1-C3)氟烷氧基、-NO2 基团、苯氧基或 (C1-C4)烷氧基、 R1 和 R2 独立地为氢原子或 (C1-C3) 烷基、 R′ 是氢原子、卤素原子、(C1-C3)烷基或(C1-C4)烷氧基、 R″ 是氢原子或 (C1-C4) 烷基、 n 是 1、2 或 3，以及 n′ 为 1 或 2。